Transfusion alternatives in transfusion medicine : TATM最新文献

Intravenous iron in digestive diseases: INTRAVENOUS IRON IN DIGESTIVE DISEASES 消化道疾病中的静脉注射铁:消化道疾病中的静脉注射铁

Transfusion alternatives in transfusion medicine : TATM Pub Date : 2012-12-01 DOI: 10.1111/J.1778-428X.2012.01170.X

F. Gomollón, J. Gisbert

{"title":"Intravenous iron in digestive diseases: INTRAVENOUS IRON IN DIGESTIVE DISEASES","authors":"F. Gomollón, J. Gisbert","doi":"10.1111/J.1778-428X.2012.01170.X","DOIUrl":"https://doi.org/10.1111/J.1778-428X.2012.01170.X","url":null,"abstract":"SUMMARY \u0000 \u0000From a global perspective, poor nutrition is the most important cause of iron deficiency and iron deficiency anemia. However, in developed countries gastrointestinal diseases are the most probable causes that should be taken into account in the differential diagnosis. Blood losses through mucosal ulceration, malabsorption, chronic inflammation, neoplasia, difficulties in intake of food, or a combination of these mechanisms can be found in various gastrointestinal diseases. Several iron compounds suitable for oral use are available, the most simple and most commonly used being iron salts such as iron sulfate or iron fumarate. However, oral iron is not always the best option. Intravenous (IV) iron has been shown to be effective in several observational and controlled studies. In cancer patients, oral iron has been shown to be effective in some studies, but IV iron has several advantages in this particular scenario: it is well tolerated, even in frail patients, and is quick to obtain a response, something rather convenient if prompt surgery is needed. IV iron is also widely used in chronic gastrointestinal blood loss caused by vascular malformations, a rather common scenario in patients on anticoagulant treatment. It is also relatively common in clinical gastroenterological practice to find anemia and iron deficiency in patients treated with nonsteroidal anti-inflammatory agents and/or antiplatelet drugs. IV iron is a useful and effective tool to treat iron deficiency in digestive diseases. Although we need more and larger trials to further define indications, protocols and follow-up rules in different pathologies, the available guidelines for the management of iron deficiency and anemia inflammatory bowel disease patients are good practical guides.","PeriodicalId":90375,"journal":{"name":"Transfusion alternatives in transfusion medicine : TATM","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/J.1778-428X.2012.01170.X","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"63389757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Role of iron replacement in the management of preoperative anemia: PREOPERATIVE IRON REPLACEMENT 铁置换在术前贫血管理中的作用:术前铁置换

Transfusion alternatives in transfusion medicine : TATM Pub Date : 2012-12-01 DOI: 10.1111/J.1778-428X.2012.01173.X

E. Bisbe

引用次数: 6

Use of intraoperative cell salvage in neurosurgery 术中细胞抢救在神经外科中的应用

Transfusion alternatives in transfusion medicine : TATM Pub Date : 2012-12-01 DOI: 10.1111/J.1778-428X.2012.01167.X

H. Roberts, C. Carroll

引用次数: 2

Vigilance of alternatives to blood components 警惕血液成分的替代品

Transfusion alternatives in transfusion medicine : TATM Pub Date : 2012-12-01 DOI: 10.1111/J.1778-428X.2012.01168.X

C. Cromey, Dafydd Thomas

引用次数: 1

Iron therapy in cancer-induced anemia: IRON THERAPY IN CANCER-INDUCED ANEMIA 铁治疗癌症性贫血:铁治疗癌症性贫血

Transfusion alternatives in transfusion medicine : TATM Pub Date : 2012-12-01 DOI: 10.1111/J.1778-428X.2012.01171.X

P. Gascón

{"title":"Iron therapy in cancer-induced anemia: IRON THERAPY IN CANCER-INDUCED ANEMIA","authors":"P. Gascón","doi":"10.1111/J.1778-428X.2012.01171.X","DOIUrl":"https://doi.org/10.1111/J.1778-428X.2012.01171.X","url":null,"abstract":"SUMMARY \u0000 \u0000Erythropoiesis-stimulating agents (ESAs) are widely used in oncology to correct the anemia associated with chemotherapy, although only 50–70% of patients show an optimal response, mostly because of functional iron deficiency (FID). As intravenous (IV) iron can overcome this FID, it has become an important adjunct to obtaining and maintaining adequate hemoglobin levels in patients with cancer receiving chemotherapy. In fact, six out of seven published randomized, controlled trials performed in cancer patients have demonstrated that IV iron given concomitantly to ESAs induces a faster and much more robust response than with ESAs alone. The possibility that giving only IV iron can also produce adequate hemoglobin responses requires further studies. However, there still exists some reluctance among many oncologists to use IV iron because of the poor safety profile observed in the past with the old iron preparations, in particular high-molecular-weight iron dextran. As the efficacy and safety of the new iron preparations have been proven, the use of IV iron should be considered in the management of anemia secondary to chemotherapy treatments.","PeriodicalId":90375,"journal":{"name":"Transfusion alternatives in transfusion medicine : TATM","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/J.1778-428X.2012.01171.X","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"63389787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Recent developments in the obstetric use of cell salvage: CELL SALVAGE IN OBSTETRICS 产科使用细胞回收的最新进展:产科中的细胞回收

Transfusion alternatives in transfusion medicine : TATM Pub Date : 2012-12-01 DOI: 10.1111/J.1778-428X.2012.01160.X

L. Peacock, V. Clark, S. Catling

{"title":"Recent developments in the obstetric use of cell salvage: CELL SALVAGE IN OBSTETRICS","authors":"L. Peacock, V. Clark, S. Catling","doi":"10.1111/J.1778-428X.2012.01160.X","DOIUrl":"https://doi.org/10.1111/J.1778-428X.2012.01160.X","url":null,"abstract":"SUMMARY \u0000 \u0000The acceptance of cell salvage in obstetrics has been hampered by concerns about amniotic fluid embolism and maternal alloimmunization. The removal of amniotic fluid debris by cell salvage has been proven, but controversy remains as to whether using one or two separate suction devices for removal of amniotic fluid and blood is necessary. There have been recent reports of hypotensive episodes occurring during re-infusion of the salvaged blood with leukodepletion filters. Bradykinin release may be the responsible agent. Maternal alloimmunization can potentially occur as the cell saver cannot differentiate between maternal and fetal red cells. However, the fetal cell transference rate in salvaged blood is of the same magnitude as during a feto-maternal hemorrhage and can be treated by appropriate administration of anti-D. Salvaged blood does not contain any coagulation factors and in massive hemorrhage these factors must be replaced in addition to the red cells. Coagulopathy in bleeding patients that have cell salvage should not be viewed as an adverse event associated with this technique, but rather as inadequate replacement of coagulation products. There is currently no evidence base that cell salvage in obstetrics reduces allogeneic transfusion or is cost-effective. A randomized controlled trial is urgently needed.","PeriodicalId":90375,"journal":{"name":"Transfusion alternatives in transfusion medicine : TATM","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/J.1778-428X.2012.01160.X","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"63397288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Washing and filtering of cell-salvaged blood - does it make autotransfusion safer? 细胞保存血液的洗涤和过滤--是否会使自体输血更安全？

Transfusion alternatives in transfusion medicine : TATM Pub Date : 2012-12-01 DOI: 10.1111/j.1778-428X.2012.01155.x

Gerhardt Konig, Jonathan H Waters

引用次数: 0

Editorial: iron therapy in clinical practice: an overview 社论:临床实践中的铁疗法:综述

Transfusion alternatives in transfusion medicine : TATM Pub Date : 2012-12-01 DOI: 10.1111/J.1778-428X.2012.01179.X

M. Muñoz

引用次数: 0

Editorial: Transfusion Alternatives in Transfusion Medicine 1999–2012 社论:1999-2012年输血医学中的输血替代方案

Transfusion alternatives in transfusion medicine : TATM Pub Date : 2012-12-01 DOI: 10.1111/J.1778-428X.2012.01176.X

K. Messmer

{"title":"Editorial: Transfusion Alternatives in Transfusion Medicine 1999–2012","authors":"K. Messmer","doi":"10.1111/J.1778-428X.2012.01176.X","DOIUrl":"https://doi.org/10.1111/J.1778-428X.2012.01176.X","url":null,"abstract":"Transfusion Alternatives in Transfusion Medicine (TATM) was launched in 1999 shortly after the Network for the Advancement of Transfusion Alternatives (NATA) was created by Professor Jean-Francois Baron (Paris, France), who served both as NATA chair and as TATM editor-inchief. At that time, clinicians and scientists had realized that the risks associated with the administration of blood components and blood-derived products were too high to be accepted by doctors and patients. Efforts were made to avoid allogeneic blood transfusions by establishing alternative methods such as preoperative autologous blood donation, normovolemic hemodilution and cell salvage autotransfusion. The annual symposia organized by NATA were a unique platform to present and discuss the various forms of alternatives to allogeneic blood transfusions in order to evaluate their potential benefits and risks. At each meeting, the actual state of artificial blood, more precisely fluorocarbons and hemoglobinbased solutions, was presented to a multidisciplinary audience. TATM was then published by LM Sante (now Med Ed Global Solutions), the agency also in charge of organizing NATA symposia. In 2002, when Professor Baron retired from his positions of NATA chair and TATM editor-in-chief, I was assigned by the NATA board of directors to take over both positions. At the end of my 3-year term, Professor Maniatis was elected as NATA chair and I was invited to continue as TATM editor-in-chief. At that time, the NATA board decided to look for a professional publisher for the journal and entrusted Wiley-Blackwell (Oxford, UK) with the publication of the journal. The publisher put high energy and efforts in relaunching TATM; however, the potential authors of articles dealing with transfusion medicine and alternatives remained reluctant to send their original papers to TATM as it was not indexed in the main medical databases, which in turn made it difficult to maintain a regular publication schedule, one of the key requirements for indexing. Although TATM was able to publish excellent review articles by leading experts on specific topics, as well as several outstanding themed issues coordinated by renowned guest editors, the board of directors finally came to the conclusion that the efforts required to maintain the journal may be more fruitfully dedicated to developing the NATA website (http://www.nataonline. com) and a continuing medical education e-learning program, while developing partnerships with indexed journals in the field of transfusion medicine. As editor-in-chief, I would like to express my sincere gratitude to the NATA board of directors for entrusting me the official journal of NATA for the last decade. Today I would like to thank all the colleagues who submitted manuscripts to TATM, the associate editors, editorial board members, reviewers and guest editors who helped the journal stick to high quality standards, and the team at Wiley-Blackwell, particularly Sam Gough and Valer","PeriodicalId":90375,"journal":{"name":"Transfusion alternatives in transfusion medicine : TATM","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/J.1778-428X.2012.01176.X","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"63389989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment of iron deficiency anemia in pregnancy and postpartum 妊娠期及产后缺铁性贫血的治疗

Transfusion alternatives in transfusion medicine : TATM Pub Date : 2012-12-01 DOI: 10.1111/J.1778-428X.2012.01172.X

C. Breymann, A. Krafft

{"title":"Treatment of iron deficiency anemia in pregnancy and postpartum","authors":"C. Breymann, A. Krafft","doi":"10.1111/J.1778-428X.2012.01172.X","DOIUrl":"https://doi.org/10.1111/J.1778-428X.2012.01172.X","url":null,"abstract":"SUMMARY \u0000Iron deficiency (ID), iron deficiency anemia (IDA) and the resulting reduction in blood reserves are one the most common problems in pregnancy. Both oral iron – the traditional treatment – and blood transfusion involve significant drawbacks. High doses of oral iron frequently cause side effects, and noncompliance is common. Therefore, intravenous iron, alone or in association with recombinant human erythropoietin (rHuEPO), has been evaluated as an alternative in the management of ID in this setting. There is increasing evidence that iron sucrose is effective for treating IDA and safe for the mother and the fetus, using the recommended dosages and treatment regimens. In the postpartum period, both iron sucrose and ferric carboxymaltose have been shown to be efficacious, alone or in combination with rHuEPO. In pregnancy and in the postpartum period, the expected hemoglobin increase and treatment times are predictable according to the present data; therefore, in the presence of moderate-to-severe anemia, it can be questioned whether it is reasonable to wait for a response to oral iron. Indications for the use of iron sucrose and ferric carboxymaltose are preexisting moderate-to-severe anemia, no effect of oral iron, side effects of oral iron, refusal of blood transfusion, limited time until delivery, coexisting risk factors (e.g. inflammatory bowel disease, renal disease), the preoperative and postoperative periods and postpartum anemia. Future fields of research include the impact of intravenous iron therapy on patient satisfaction and quality of life, costs, hospital length of stay, blood transfusion rate, mortality rate, and other outcomes such as breastfeeding behavior and neonatal outcomes (e.g. birth weight, prematurity and neonatal iron stores).","PeriodicalId":90375,"journal":{"name":"Transfusion alternatives in transfusion medicine : TATM","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/J.1778-428X.2012.01172.X","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"63389803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 10